March 9, 2017—Syncope has many causes and clinical presentations; the incidence depends on the population being evaluated. The purpose of this ACC/AHA/HRS guideline is to provide contemporary, accessible, and succinct guidance on the management of adult and pediatric patients with suspected syncope.
Search for "" returned 3 matches
Beta-Blocker Therapy for Long QT Syndrome and Catecholaminergic Polymorphic Ventricular Tachycardia: Are All Beta-Blockers Equivalent?28108
September 18, 2016—Drug therapy with beta-blockers represents the therapeutic mainstay for both LQTS and CPVT. The goal of the document is to help clinicians understand the importance of beta-blocker therapy in these two genetic disorders, as well as to provide clinical guidance on the choice of agents. Nadolol, when available, has been the preferred beta-blocker utilized by the largest LQTS/CPVT specialty centers throughout the world for the past 25 years.
2011 HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies23850
August 2011—Genetic testing is increasingly important in determining potential cardiac conditions in patients and is used in clinical settings more than ever before. To ensure that physicians have up-to-date knowledge of the evolving role of genetic testing for sudden death predisposing, genetic heart diseases in cardiology, which can be lifesaving for some patients, the Heart Rhythm Society and the European Heart Rhythm Association have prepared HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Channelopathies and Cardiomyopathies.
|This document was reaffirmed on April 11, 2018, and will be formally assessed by April 2023.|